Company: SQM
Filing Date: 2025-11-19
Form Type: 6-K
Source: 0000909037-25-000042
Chunk: 2

Company: CHEMICAL & MINING CO OF CHILE INC
Filing Date: 2025-11-19
Form: 6-K
Chunk 2
---
: “Positive results were not limited to lithium. Our Iodine and Plant Nutrition division also delivered solid performance. In iodine, we continue to observe prices at a high level due to current balance between supply and demand. In addition, construction of our seawater pipeline is now more than 80% complete, a key milestone that will enable us to bring additional product to the market if required earlier than expected.” He added: “In the fertilizer business, we observed healthy demand and firmer prices across most of our key markets.” 1 excluding spodumene concentrate sales from Australia

| SQM S.A. 3Q2025 Earnings release |     | 1 |

The CEO closed by saying: “Finally, as announced last week by SQM and Codelco, we have obtained authorization from the Chinese antitrust authority (SAMR) for our partnership to jointly develop the Atacama salt flat. This is a major milestone, and we look forward to advancing this joint venture, which will allow Chile to play a leading role in the development of new clean technologies.” Capex Update We have reviewed our capital expenditure program for the 2025–2027 period and now estimate total capex at US$2.7 billion. Some investment decisions have been delayed, but we have been able to do so without impacting on our ability to reach the production and sales objectives set for each of our divisions. This capital expenditure plan is expected to be evenly distributed over the three years, with approximately 25% allocated to maintenance. This capex program considers the investments needed to finalize the seawater pipeline, the Maria Elena iodine production site, along with the expansion of our lithium carbonate and lithium hydroxide capacity in Chile. It is also included the investments needed for the expansion of the Mt. Holland project, along with the initial investments to develop the Andover project, both in Australia. Disbursements related to the latter two projects remain contingent upon reaching final investment decisions with our partners. Segment Analysis Lithium and Derivatives Revenues for lithium and derivatives totaled US$1,551.8 million during the nine months ended September 30, 2025, a decrease of 9.2% compared to US$1,709.3 million recorded for the nine months ended September 30, 2024. Revenues for lithium and derivatives totaled US$603.7 million during the third quarter of 2025, an increase of 21.4% compared to US$497.2 million recorded for